Weight-loss drugs could be a boon for insurers, but it is too soon to tell whether the industry will be transformed, the head ...
Novo Nordisk got European approval to move forward with its planned buyout of U.S.-based drug manufacturer Catalent, which produces much of its popular obesity drug Wegovy. That leaves the U.S.
Apollo-Backed Novolex to Buy Pactiv Evergreen for $3.22 Billion Novolex, a packaging company backed by Apollo Global Management, struck a deal to buy publicly traded Pactiv Evergreen for around $3.22 ...
Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.
Novo Nordisk's Lotte Bjerre Knudsen says her determination is a key part of the success, but she also stays humble.
The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.
They are currently approved for treating diabetes, obesity and those with a history of cardiovascular disease in people who ...
Joe Breen, 38, is one of thousands of people whose experiences with GLP-1s such as Ozempic and Wegovy have radically changed their relationship with alcohol. Are these drugs the future for treating ...
The FDA put both peptides on its shortage list in 2022. Semaglutide is still on that list, while the FDA lifted its shortage ...